Australia markets close in 2 hours 12 minutes

Genmab A/S (GMAB)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
28.01+0.01 (+0.04%)
At close: 04:00PM EDT
27.71 -0.30 (-1.07%)
After hours: 07:59PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close28.00
Open28.51
Bid27.97 x 100
Ask28.01 x 100
Day's range27.90 - 28.53
52-week range26.32 - 42.72
Volume544,958
Avg. volume488,495
Market cap18.333B
Beta (5Y monthly)0.79
PE ratio (TTM)23.34
EPS (TTM)1.20
Earnings date01 Aug 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est40.93
  • GlobeNewswire

    Transactions in Connection with Share Buy-back Program

    Company Announcement COPENHAGEN, Denmark; May 27, 2024 – Genmab A/S (Nasdaq: GMAB). On March 15, 2024, Genmab announced the initiation of a share buy-back program to repurchase up to DKK 3.5 billion worth of shares.The share buy-back program is expected to be completed no later than December 16, 2024. The following transactions were executed under the program from May 20, 2024 to May 24, 2024: Trading PlatformNo. of sharesAverage price (DKK)Total value (DKK)Accumulated through last announcement

  • Business Wire

    Genmab to Showcase Data in Various Patient Populations to be Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting

    COPENHAGEN, Denmark, May 23, 2024--Genmab A/S (Nasdaq: GMAB) announced today that multiple abstracts evaluating epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, tisotumab vedotin, an antibody-drug conjugate (ADC), and acasunlimab (also known as GEN1046/BNT311), an investigational bispecific antibody, will be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, being held in Chicago, IL and virtually, May 31-June 2, 2024.

  • Business Wire

    Genmab Completes Acquisition of ProfoundBio

    COPENHAGEN, Denmark, May 21, 2024--Genmab A/S (Nasdaq: GMAB) announced today that it has completed its acquisition of ProfoundBio, Inc., a clinical-stage biotechnology company developing next-generation antibody-drug conjugates (ADC)s and ADC technologies for the treatment of cancers in an all-cash transaction of USD 1.8 billion (subject to adjustment for ProfoundBio’s closing net debt and transaction expenses).